高强度与低强度无创正压通气对慢性阻塞性肺疾病急性加重患者气管插管需求的影响:HAPPEN随机临床试验
HAPPEN随机临床试验在中国30个普通呼吸科非重症监护病房开展,纳入慢性阻塞性肺疾病急性加重且低强度无创正压通气6小时后PaCO2仍大于45 mmHg的患者。患者1:1随机接受高强度无创正压通气(潮气量10 mL/kg至15 mL/kg预测体重,n=147)或继续低强度无创正压通气(潮气量6 mL/kg至10 mL/kg预测体重,n=153)。主要终点为住院期间符合预设气管插管标准,高强度组7/147(4.8%)vs低强度组21/153(13.7%),绝对差-9.0%(95%CI -15.4%至-2.5%),单侧P=0.004;实际气管插管率两组无显著差异(3.4% [5/147] vs 3.9% [6/153],绝对差-0.5% [95%CI -4.8%至3.7%],P=0.81)。高强度组腹胀更常见(37.4% [55/147] vs 25.5% [39/153])。
要点
- 纳入标准:慢性阻塞性肺疾病急性加重,低强度无创正压通气6小时后PaCO2大于45 mmHg。
- 高强度无创正压通气目标潮气量10 mL/kg至15 mL/kg预测体重,低强度目标潮气量6 mL/kg至10 mL/kg预测体重。
- 主要终点符合预设插管标准:高强度组4.8%(7/147)vs低强度组13.7%(21/153),绝对差-9.0%(95%CI -15.4%至-2.5%),单侧P=0.004。
- 实际气管插管率:高强度组3.4%(5/147)vs低强度组3.9%(6/153),绝对差-0.5%(95%CI -4.8%至3.7%),P=0.81,无显著差异。
- 不良事件:腹胀在高强度组37.4%(55/147)较低强度组25.5%(39/153)更常见。
适用人群与场景
- 慢性阻塞性肺疾病急性加重且高碳酸血症患者,在30个中国医院普通呼吸科非重症监护病房住院。
- 纳入条件:接受低强度无创正压通气6小时后PaCO2大于45 mmHg。
诊断标准与关键阈值
- 低强度无创正压通气6小时后PaCO2大于45 mmHg为入组高碳酸血症阈值。
- 主要终点为住院期间符合预设气管插管标准(由预设标准定义)。
处置流程与药物剂量
- 高强度无创正压通气:调整吸气正压使潮气量达到预测体重10 mL/kg至15 mL/kg(n=147)。
- 低强度无创正压通气:调整吸气正压使潮气量达到预测体重6 mL/kg至10 mL/kg(n=153)。
- 低强度组患者符合预设气管插管标准时允许交叉到高强度无创正压通气。
研究设计与关键结果
- 随机临床试验,30个中国医院普通呼吸科非重症监护病房,2019年1月3日至2022年1月31日,最后90天随访2022年4月22日;纳入300例完成试验患者(平均年龄73岁[SD 10岁],68%男性),全部纳入分析。
- 主要终点符合预设气管插管标准:高强度组7/147(4.8%)vs低强度组21/153(13.7%),绝对差-9.0%(95%CI -15.4%至-2.5%),单侧P=0.004。
- 实际气管插管率:高强度组3.4%(5/147)vs低强度组3.9%(6/153),绝对差-0.5%(95%CI -4.8%至3.7%),P=0.81,无显著差异。
- 腹胀:高强度组37.4%(55/147)vs低强度组25.5%(39/153)。
- 试验在数据安全监查委员会和试验指导委员会对前300例患者进行中期分析后终止。
证据类型、等级与局限
- 证据类型:随机临床试验(RCT)。
- 试验注册:ClinicalTrials.gov标识NCT02985918。
- 局限:低强度组患者符合预设插管标准时允许交叉到高强度无创正压通气;实际气管插管率组间无显著差异。
对床旁实践的改变
- 对慢性阻塞性肺疾病急性加重伴高碳酸血症(低强度无创正压通气6小时后PaCO2大于45 mmHg)患者,高强度无创正压通气(目标潮气量10 mL/kg至15 mL/kg预测体重)较高强度无创正压通气(目标潮气量6 mL/kg至10 mL/kg预测体重)显著减少符合预设气管插管标准,但实际气管插管率无显著差异;低强度组允许交叉到高强度无创正压通气。
- 高强度无创正压通气组腹胀更常见(37.4% [55/147] vs 25.5% [39/153])。
指南或共识出处
- HAPPEN随机临床试验,发表于JAMA。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The effect of high-intensity noninvasive positive pressure ventilation (NPPV) on the need for endotracheal intubation in patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD) is unknown.
OBJECTIVE: To determine whether the use of high-intensity NPPV vs low-intensity NPPV reduces the need for endotracheal intubation in patients with an acute exacerbation of COPD and hypercapnia.
DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted at 30 general respiratory non-intensive care unit wards of Chinese hospitals from January 3, 2019, to January 31, 2022; the last 90-day follow-up was on April 22, 2022. The included patients had an acute exacerbation of COPD and a Paco2 level greater than 45 mm Hg after receiving 6 hours of low-intensity NPPV.
INTERVENTIONS: Patients were randomized 1:1 to receive high-intensity NPPV with inspiratory positive airway pressure that was adjusted to obtain a tidal volume 10 mL/kg to 15 mL/kg of predicted body weight (n = 147) or to continue receiving low-intensity NPPV with inspiratory positive airway pressure that was adjusted to obtain a tidal volume of 6 mL/kg to 10 mL/kg of predicted body weight (n = 153). Patients in the low-intensity NPPV group who met the prespecified criteria for the need for endotracheal intubation were allowed to crossover to high-intensity NPPV.
MAIN OUTCOMES AND MEASURES: The primary outcome was the need for endotracheal intubation during hospitalization, which was defined by prespecified criteria. There were 15 prespecified secondary outcomes, including endotracheal intubation.
RESULTS: The trial was terminated by the data and safety monitoring board and the trial steering committee after an interim analysis of the first 300 patients. Among the 300 patients who completed the trial (mean age, 73 years [SD, 10 years]; 68% were men), all were included in the analysis. The primary outcome of meeting prespecified criteria for the need for endotracheal intubation occurred in 7 of 147 patients (4.8%) in the high-intensity NPPV group vs 21 of 153 (13.7%) in the low-intensity NPPV group (absolute difference, -9.0% [95% CI, -15.4% to -2.5%], 1-sided P = .004). However, rates of endotracheal intubation did not significantly differ between groups (3.4% [5/147] in the high-intensity NPPV group vs 3.9% [6/153] in the low-intensity NPPV group; absolute difference, -0.5% [95% CI, -4.8% to 3.7%], P = .81). Abdominal distension occurred more frequently in the high-intensity NPPV group (37.4% [55/147]) compared with the low-intensity NPPV group (25.5% [39/153]).
CONCLUSIONS AND RELEVANCE: Patients with COPD and persistent hypercapnia in the high-intensity NPPV group (vs patients in the low-intensity NPPV group) were significantly less likely to meet criteria for the need for endotracheal intubation; however, patients in the low-intensity NPPV group were allowed to crossover to high-intensity NPPV, and the between-group rate of endotracheal intubation was not significantly different.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02985918.
参考来源
- Luo Z, Li Y, Li W, et al. Effect of High-Intensity vs Low-Intensity Noninvasive Positive Pressure Ventilation on the Need for Endotracheal Intubation in Patients With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease: The HAPPEN Randomized Clinical Trial. JAMA. 2024. PMID: 39283649. doi:10.1001/jama.2024.15815
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。